ImmunoGen Inc reports results for the quarter ended in September - Earnings Summary

ImmunoGen

02/11/2023 13:33

* ImmunoGen Inc  IMGN.OQ  reported quarterly adjusted
earnings of
10 cents​​ per share for the quarter ended in September, higher
than the same quarter last year, when the company reported EPS
of -31 cents.  The mean expectation of thirteen analysts for the
quarter was for earnings of 4 cents per share. Wall Street
expected results to range from zero cents to 13 cents per share.
    * Revenue rose 637.7% to $113.43 million from a year ago;
analysts
expected $106.42 million. 
    * ImmunoGen Inc's reported EPS for the quarter was 10
cents​.
    * The company reported quarterly net income of $30.75
million.
    * ImmunoGen Inc shares had fallen by 5.9% this quarter and
gained 201.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 63.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for ImmunoGen
Inc is
$24.00 

This summary was machine generated from LSEG data November 2 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      0.04           0.10           Beat
 Jun. 30 2023      -0.14          -0.02          Beat
 Mar. 31 2023      -0.25          -0.16          Beat
 Dec. 31 2022      -0.30          -0.23          Beat